Moderna, Inc. in 1 story
The narratives MRNA currently appears in, with its side and exposure in each.
Bull side
0 storiesNo bull-side stories for MRNA yet.
Bear side
1 story- China Becomes Pharma's Global R&D Engine
MRNA in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
The abundance of clinically advanced external assets makes investors less willing to fund prolonged, expensive platform-based pipeline buildouts.